CORALVILLE, Iowa, Sept. 23, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that Sven Guenther, Ph.D., Executive Vice President of Research & Development, will be a featured presenter at the 9th Annual Pain & Migraine Therapeutics Summit being held September 23-24, 2015, in Washington D.C.
In a presentation titled, "The Search for New Pain Therapeutics with Low Inherent Abuse Potential—A Case for Prodrugs," Dr. Guenther will discuss different approaches for finding new pain drugs with improved side effect and abuse profiles. Specifically, Dr. Guenther will highlight advances in the development of prodrugs and the progress of KemPharm's most advanced pain product candidates, KP201/APAP, a prodrug of hydrocodone in combination with acetaminophen, as well as KP511, a prodrug of hydromorphone. Dr. Guenther's presentation is scheduled for September 23, 2015, at 2:15 p.m., ET.
Dr. Guenther commented, "It is an honor to present KemPharm's prodrug technology at the 9th Annual Pain & Migraine Therapeutics Summit and I look forward to highlighting the potential that prodrugs may offer in improving the side effect and abuse profile of prescription pain medications."
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
Caution Concerning Forward Looking Statements
This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21 E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. These forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: KemPharm's financial resources and whether they will be sufficient to meet KemPharm's business objectives and operational requirements; results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by KemPharm's intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. KemPharm's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning KemPharm's business are described in additional detail in KemPharm's Registration Statement on Form S-1 (Registration No. 333-202660) declared effective April 15, 2015, and KemPharm's other Periodic and Current Reports filed with the Securities and Exchange Commission. KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
|For KemPharm, Inc.:||Media / Investor Contacts:|
|Gordon K. "Rusty" Johnson||Jason Rando / Joshua Drumm, Ph.D.|
|319-665-2575||Tiberend Strategic Advisors, Inc.|
|email@example.com||212-375-2665 / 2664|